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Objectives The purpose of this study was to characterize the determinants of plaque progression despite achieving very low
levels of low-density lipoprotein cholesterol (LDL-C).
Background Despite achieving very low levels of LDL-C, many patients continue to demonstrate disease progression and have
clinical events.
Methods A total of 3,437 patients with coronary artery disease underwent serial intravascular ultrasound examination in
7 clinical trials. Patients who achieved an on-treatment LDL-C level of 70 mg/dl (n  951) were stratified as
progressors (n  200) and nonprogressors (n  751) and compared.
Results Despite achieving LDL-C 70 mg/dl, 20% of patients continued to progress. There were no demographic dif-
ferences between groups. Progressors demonstrated higher baseline levels of glucose (117.1  42.5 mg/dl vs.
112.1  40.0 mg/dl, p  0.02), triglycerides (157.5 mg/dl vs. 133.0 mg/dl, p  0.004), and a smaller de-
crease of apolipoprotein B (25.1  3.4 mg/dl vs. 27.4  3.35 mg/dl, p  0.01) at follow-up. Multivariable
analysis revealed that independently associated risk factors of progression in patients with LDL-C 70 mg/dl in-
cluded baseline percent atheroma volume (p  0.001), presence of diabetes mellitus (p  0.02), increase in systolic
blood pressure (p  0.001), less increase in high-density lipoprotein cholesterol (p  0.01), and a smaller decrease in
apolipoprotein B levels (p  0.001), but not changes in C-reactive protein (p  0.78) or LDL-C (p  0.84).
Conclusions Residual risk factors are associated with the likelihood of disease progression in patients who achieve very low
LDL-C levels. In addition, the association between apolipoprotein B and atheroma progression highlights the po-
tential importance of LDL particle concentration in patients with optimal LDL-C control. This finding highlights
the need for intensive modification of global risk in patients with coronary artery disease. (J Am Coll Cardiol
2010;55:2736–42) © 2010 by the American College of Cardiology Foundationd
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Vompelling evidence from observational and interventional
tudies highlight the pivotal role of hyperlipidemia in the
athogenesis of atherosclerotic cardiovascular disease. Virtually
ll such studies demonstrate a direct relationship between
eduction in low-density lipoprotein cholesterol (LDL-C) and
ardiovascular morbidity and mortality (1–3). Accordingly,
urrent lipid-lowering guidelines focus on LDL-C reduction
s a principal target for primary and secondary prevention of
ardiovascular disease (4). Recent clinical trials have demon-
trated an incremental benefit from use of more intensive lipid-
owering regimens (5,6), and more recent iterations of guidelines
mphasize more aggressive target levels for LDL reduction (7).
See page 2743
Arterial wall imaging with intravascular ultrasound
IVUS) enables serial quantitation of coronary atheroscle-
otic plaque burden. In clinical trials, IVUS has been
mployed to evaluate the effect of various medical therapies
n disease progression. An initial study demonstrated the
bility of intensive LDL-C lowering with high-dose statin
herapy to arrest atheroma progression (3). A subsequent
tudy demonstrated regression of atherosclerosis in patients
ho achieve LDL-C levels 70 mg/dl (8).
However, not all patients with a LDL-C level 70 mg/dl
xhibit regression of coronary atherosclerosis on serial IVUS
maging. The residual risk factors associated with progression
espite achieving very low LDL-C levels remain to be eluci- rated. Therefore, the objective of the current analysis was to
haracterize the clinical factors that correlate with atheroma
rogression in patients who achieve a LDL-C level 70 mg/dl.
ethods
election of subjects and study design. The current anal-
sis pooled data from 7 prospective atherosclerosis progres-
ion/regression IVUS trials, including a total population of
,437 patients with established coronary heart disease.
atients with an on-treatment LDL-C level 70 mg/dl were
lassified as progressors (5% increase in percent atheroma
olume [PAV]) or nonprogressors. These 7 studies, which
ncluded a wide range of pharmacological interventions, were
he CAMELOT (Comparison of Amlodipine Versus Enala-
ril to Limit Occurrences of Thrombosis) study (9), the
EVERSAL (Reversal of Atherosclerosis With Aggressive
ipid Lowering) (6) study, the ACTIVATE (Acyl:
holesterol Acyltransferase Intravascular Atherosclerosis
reatment Evaluation) study (10), the ASTEROID (A
tudy to Evaluate the Effect of Rosuvastatin on Intravas-
ular Ultrasound-Derived Coronary Atheroma Burden)
rial (8), the ILLUSTRATE (Investigation of Lipid Level
anagement Using Coronary Ultrasound to Assess Reduc-
ion of Atherosclerosis by Cholesteryl Ester Transfer Pro-
ein Inhibition and High-Density Lipoprotein Elevation)
tudy (11), the PERISCOPE (Comparison of Pioglitazone
ersus Glimepiride on Progression of Coronary Atheroscle-osis in Patients With Type 2 Diabetes) trial (12), and
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Very Low Levels of LDL-C, ApoB, Plaque Progression June 15, 2010:2736–42the STRADIVARIUS (Effect of
Rimonabant on Progression of
Atherosclerosis in Patients With
Abdominal Obesity and Coro-
nary Artery Disease) study (13).
These were clinical trials that em-
ployed serial IVUS examination to
assess the impact of intensive lipid
lowering, antihypertensive ther-
apy, acyl:cholesterol acyltransferase
inhibition, cholesteryl ester trans-
fer protein inhibition, oral glucose-
lowering agents, and endocannabi-
noid type 1 receptor antagonists on
the progression of coronary ath-
erosclerosis. All patients were re-
quired to have coronary artery dis-
ase, defined as having at least 1 lumen narrowing 20% in a
ajor epicardial coronary artery on a diagnostic coronary
ngiogram performed for a clinical indication.
cquisition and analysis of IVUS images. The acquisi-
ion and analysis of ultrasonic images have been described in
etail previously (8–13). In brief, after anticoagulation
herapy and administration of intracoronary nitroglycerin, an
maging catheter containing a high-frequency ultrasound
ransducer (30 to 40 MHz) was inserted distally within a
oronary artery. The target vessel for imaging was required to
ave a segment of at least 30 mm in length that contained no
umen narrowing 50%, had not undergone previous revas-
ularization, and was not considered to be the culprit vessel for
prior myocardial infarction. Continuous ultrasonic imaging
as acquired during withdrawal of the catheter through the
egment of artery at a constant rate of 0.5 mm/s. Images were
tored on videotape and subsequently digitized for analysis in a
ingle core laboratory by persons who were blinded to the
linical characteristics and treatment status of the patients.
atching arterial segments were defined from the images
cquired at the baseline and follow-up studies on the basis of
he anatomic location of proximal and distal side branches
fiduciary points). Images spaced precisely 1 mm apart in the
egment of interest were selected for analysis.
The leading edge of the lumen and the external elastic
embrane (EEM) were defined by manual planimetry. The
laque area was defined as the difference in area occupied by
he lumen and EEM borders. The total atheroma volume (TAV)
as calculated by summation of the plaque area calculated for each
easured image and subsequently normalized to account for
ifferences in segment length between subjects:
AVnormalized 
 (EEMarea Lumenarea)
Number of images in Pullback

Median number of images in whole cohort
The percent atheroma volume (PAV) was calculated as
he proportion of vessel wall volume occupied by athero-
Abbreviations
and Acronyms
Apo  apolipoprotein
EEM  external elastic
membrane
HDL-C  high-density
lipoprotein cholesterol
IVUS  intravascular
ultrasound
LDL-C  low-density
lipoprotein cholesterol
PAV  percent atheroma
volume
TAV  total atheroma
volumeclerotic plaque: ePAV 
 (EEMarea  Lumenarea)
 (EEMarea)
 100
Volumes occupied by the lumen and EEM were similarly
alculated by summation of their respective areas in each
easured image and subsequently normalized to account for
ifferences in segment length between subjects.
tatistical analyses. Patients with an on-treatment follow-up
DL-C 70 mg/dl (n  951) were classified as progressors
5% increase in PAV, n  200) or nonprogressors (n  751).
aseline demographics, medical history, baseline and follow-up
iochemical data (lipids, C-reactive protein, blood pressure,
lucose, and apolipoprotein B [apoB]), as well as IVUS
easurements were compared between the groups. Two-
ample t tests were performed for normally distributed contin-
ous variables and Wilcoxon rank-sum tests for non-normally
istributed continuous variables, and chi-square tests were run
or categorical variables. Serial changes in biochemical data and
n IVUS measurements between the groups were assessed
sing mixed modeling methodology adjusting for their baseline
ounterparts. Trial was considered a random effect in the
ixed modeling. Generalized estimating equations models
ere constructed for obtaining clinical predictors of progres-
ors, with the assumption that progression in different trials
as statistically independent with each other whereas the
rogression data within each trial was uniformly correlated. A
-sided probability value of 0.05 was considered statistically
ignificant. All the analyses were performed using the SAS
oftware version 9.1.3 (SAS Institute, Cary, North Carolina).
esults
linical and biochemical characteristics of subjects. No
ignificant differences in clinical characteristics and use of
edications at baseline and during the course of the studies
ere observed in patients stratified according to the presence or
bsence of atheroma progression (Table 1). The degree of risk
actor control at baseline and follow-up are summarized in
able 2. At baseline, progressors had higher levels of triglyc-
rides (157.5 mg/dl, interquartile range 107.0 to 212.5 mg/dl
s. 133.0 mg/dl, interquartile range 96.0 to 188.9 mg/dl, p 
.004) and glucose (117.1  42.5 mg/dl vs. 112.1  40.0
g/dl, p  0.02). At follow-up, progressors demonstrated
igher levels of triglycerides (121.1 mg/dl vs. 111.2 mg/dl, p
.03), systolic blood pressure (130.8  14.8 mm Hg vs. 128.3
13.8 mm Hg, p 0.047), apoB (65.9 16.6 mg/dl vs. 61.9
16.0 mg/dl, p 0.002), and LDL-C (58.4 8.7 mg/dl vs.
6.5  9.8 mg/dl, p  0.02).
easures of atheroma burden and vessel dimensions.
easures of atheroma burden and vessel dimensions at
aseline and on serial evaluation are summarized in Table 3.
f interest, the mean duration of follow-up to the time of
he second IVUS study was in fact shorter for patients who
emonstrated progression (654.3  105.2 days vs. 674.4 
07.3 days, p  0.02). Progressors demonstrated less
xtensive disease at baseline, with a smaller PAV (34.5 
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m3 vs. 192.4  79.1 mm3, p  0.001), and larger lumen
olume (322.7  124.5 mm3 vs. 293.9  107.8 mm3, p 
.008). Despite the presence of less atherosclerosis, the
EM volume did not differ between the groups (491.9 
72.6 mm3 vs. 486.3  164.9 mm3, p  0.91). In addition
o predictable greater progression of PAV (3.83  0.2%
s. 1.1  0.2%, p  0.001) and TAV (8.4  1.9 mm3
s. 10.4  1.6 mm3, p  0.001), progressors demon-
trated greater reductions in both EEM volume (21.6 
.8 mm3 vs.13.4 3.0 mm3, p 0.01) and lumen volume
31.7  2.6 mm3 vs. 2.8  1.9 mm3, p  0.001).
In comparison of patients with an on-treatment LDL-C
70 mg/dl, patients with LDL-C 70 mg/dl demonstrated
ess progression of PAV (0.53 0.24% vs. 0.05 0.26%, p
.001) and TAV (2.54 2.0 mm3 vs.5.90 2.1 mm3, p
.001), and were less likely to undergo substantial disease progres-
ion (30.4% vs. 21%, p 0.0001). Nevertheless, it is important
o note that 1 in 5 subjects with LDL-C 70 mg/dl demon-
trated substantial disease progression.
ndependent predictors of atheroma progression at
DL-C <70 mg/dl. Multivariable analysis controlling for all
nivariate predictors revealed that independently associated
isk factors of atheroma progression in patients with a LDL-C
linical Characteristics and Usef Est blished Medical Therapi s in Patients,rogressors nd Nonprogr ssors
Table 1
Clinical Characteri tics and Use
of Established Medical Therapies in Patients,
Progressors and Nonprogressors
Characteristic
Progressors
(n  200)
Nonprogressors
(n  751) p Value
Age, yrs 59.3 10.0 59.3 9.3 0.87
Female 30.5 26.4 0.24
Hypertension 79.5 83.6 0.17
Current smoker 19.8 16.1 0.26
BMI, kg/m2 31.2 6.4 30.9 5.9 0.68
Diabetes mellitus 32.5 29.8 0.47
Metabolic syndrome 59.0 54.9 0.30
History of MI 29.0 30.6 0.66
History of CABG 5.2 2.8 0.13
History of PCI 40.7 47.0 0.15
Statin use
Baseline 69.5 69.9 0.91
Concomitant 97.0 98.3 0.26
Concomitant high dose 51.9 57.2 0.19
Beta-blocker use
Baseline 75.5 77.6 0.52
Concomitant 77.0 79.6 0.42
ACE inhibitor use
Baseline 48.5 51.0 0.53
Concomitant 58.0 55.1 0.47
Aspirin use
Baseline 94.0 94.5 0.77
Concomitant 94.0 94.5 0.77
alues are mean SD or %. Concomitant high-dose statin therapy was defined as atorvastatin 40
r 80 mg, simvastatin 80 mg, or rosuvastatin 20 or 40 mg.
ACE angiotensin-converting enzyme; BMI body mass index; CABG coronary artery bypass
rafting; MI  myocardial infarction; PCI  percutaneous coronary intervention.evel 70 mg/dl included baseline PAV (p  0.001), diabetes Tellitus (p 0.02), greater increases in systolic blood pressure
p  0.001), a smaller increase in high-density lipoprotein
holesterol (HDL-C) (p 0.01), and smaller decrease in apoB
evels (p  0.001). Neither changes in LDL-C (p  0.84) or
-reactive protein (p  0.78) were associated with the likeli-
ood of atheroma progression in patients with very low
DL-C levels (Fig. 1). There was no difference in the
omposite end point of death, myocardial infarction, and
troke between progressors and nonprogressors (1.8% vs.
.9%, p  0.77).
iscussion
e investigated the predictors of plaque progression in
atients achieving very low levels of LDL-C. Despite
chieving intensive control of LDL-C (mean on-treatment
evel 58.4 mg/dl), 1 in 5 of these patients demonstrated
ngoing disease progression. Multivariable analysis revealed
hat patients were more likely to progress if they had diabetes,
reater increases in systolic blood pressure, smaller increases in
DL-C, and smaller decreases in apoB. These results have
mportant implications for the understanding of the potential
mpact of residual risk factors that promote progression in
atients with very low levels of LDL-C. This analysis high-
ights the importance of lipid and nonlipid factors, in addition
o LDL-C in the prevention of coronary heart disease.
Clinical trials using statins to lower LDL-C have dem-
nstrated reductions in cardiovascular events and atheroma
rogression (5,6). The reduction in events and atheroma
rogression were related to the magnitude of absolute reduc-
ions in LDL-C. Angiographic and IVUS studies have dem-
nstrated regression of coronary disease with aggressive
DL-C lowering strategies (8,14). However, in all of these
rials, many patients achieving very low levels of LDL-C
ubsequently experienced a cardiovascular event or demon-
trated progression of coronary atherosclerosis.
The present analysis suggests that optimal control of
DL-C represents only 1 component of a successful strategy
or secondary prevention in patients with established coronary
rtery disease. The current findings that additional risk factors
redict the likelihood of undergoing disease progression sup-
ort the concept that atherosclerosis is a multifactorial process
nd is likely to respond best to therapeutic approaches that
odify global risk, rather than a strategy that targets 1
ndividual risk factor. As a result, lifestyle measures and
harmacological regimens are likely to have the most profound
mpact in reducing the burden of cardiovascular disease.
These observations highlight the importance of mixed
yslipidemia in the propagation of coronary artery disease, and
upport reports that these factors predict residual clinical risk in
arge clinical trials of statin therapy (15,16). That is particularly
mportant in the setting of abdominal adiposity and the
etabolic syndrome, which are each associated with the
evelopment of this atherogenic dyslipidemic phenotype (17).
he potential impact of lowering triglycerides and raising
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s currently being investigated in large clinical trials.
The importance of atherogenic dyslipidemic factors is also
ighlighted by the observation that smaller reductions in levels
f apoB predict progression, despite achieving a very low
DL-C level. These findings underscore the potential impor-
ance of apoB, a measure of LDL particle concentration.
ncreasing interest has focused on the additional prognostic
nformation that may be generated by assessment of measures
f LDL particle size and concentration. Studies have shown
hat cholesterol-depleted small LDL particles often accom-
any low HDL-C and elevated triglyceride levels (18–20).
onsistent with this, recent reports have demonstrated discor-
ance between LDL particle numbers and LDL-C in subjects
ith the metabolic syndrome (21) and diabetes (22). Numer-
us investigators have reported that measures of apoB or LDL
article concentration predict residual risk in patients with
pparent optimal control of LDL-C, and potentially highlight
patient who might benefit from more intensive lipid-
Measures of Risk Factor Control in ProgressorsTable 2 Measures of Risk Factor Control in
Parameter Progressors (n
Triglycerides, mg/dl
Baseline 157.5 (107.0,
Follow-up 121.1 (90.5, 1
Change 17.9 7
HDL cholesterol, mg/dl
Baseline 42.4 1
Follow-up 49.9 1
Change 4.9 2
Systolic blood pressure, mm Hg
Baseline 127.8 1
Follow-up 130.8 1
Change 2.5 0
Diastolic blood pressure, mm Hg
Baseline 75.4 9
Follow-up 75.5 7
Change 0.04.1 0
Glucose, mg/dl
Baseline 117.1 4
Follow-up 118.4 3
Change 8.7 4
Apolipoprotein B, mg/dl
Baseline 94.0 3
Follow-up 65.9 1
Change 25.1 3
LDL cholesterol, mg/dl
Baseline 94.3 3
Follow-up 58.4 8
Change 32.2 2
C-reactive protein, mg/l
Baseline 2.5 (1.2, 5.2
Follow-up 1.8 (0.9, 3.9
Change 0.04 (1.08,
Results expressed as mean  SD or median (interquartile range) w
mean  SEM changes of parameters after controlling for baseline lev
HDL  high-density lipoprotein; LDL  low-density lipoprotein.owering strategies (23,24). Furthermore, a large case-control ctudy has demonstrated that the apoB/apoA1 ratio is the
trongest biochemical predictor of incident myocardial infarc-
ion, underscoring the potential importance of measure of
ipoprotein particles, in contrast to cholesterol content (25).
he association between the presence of greater numbers of
mall, dense LDL particles in patients with hypertriglyceride-
ia and low HDL-C identifies a patient who harbors sub-
tantial cardiovascular risk even if LDL-C levels are below
reatment goals. Further studies are required to determine
hether specifically targeting patients with more intensive
ipid-lowering therapy on the basis of abnormal measures of
DL particles.
Relatively small increases in blood pressure were found to
ndependently predict atheroma progression. These small
ises occurred within the blood pressure range currently
onsidered to be well controlled, and further highlight that
laque can continue to accumulate within the artery wall in
atients who are pre-hypertensive (26). These findings are
onsistent with observations from population studies that
Nonprogressorsressors and Nonprogressors
) Nonprogressors (n  751) p Value
133.0 (96.0, 188.9) 0.004
111.2 (85.3, 156.5) 0.03
21.4 6.7 0.44
41.7 11.3 0.59
50.7 18.2 0.37
5.4 2.6 0.40
127.1 16.9 0.815
128.3 13.8 0.047
1.1 0.43 0.08
74.6 9.2 0.28
74.9 8.1 0.39
0.0 0.4 0.93
112.1 40.0 0.02
114.7 34.2 0.25
9.7 34.1 0.001
90.0 37.0 0.11
61.9 16.0 0.002
27.4 3.35 0.01
90.2 36.2 0.21
56.5 9.8 0.02
33.3 2.4 0.11
2.4 (1.1, 5.2) 0.45
1.6 (0.8, 3.7) 0.50
0.00 (0.80, 0.80) 0.70
normally distributed (triglyceride, C-reactive protein); least squaresandProg
 200
212.5)
81.4)
.5
1.7
8.3
.6
7.3
4.8
.7
.3
.3
.5
2.5
9.7
1.8
7.0
6.6
.4
7.0
.7
.5
)
)
0.99)
hen notardiovascular risk begins to increase once blood pressure
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oth LDL-C and blood pressure have an incremental
mpact on disease progression (28). Accordingly, the results
f the current analysis further support findings from clinical
rials of benefit of targeting both blood pressure and
yslipidemia to prevent cardiovascular events.
It is also important to note that baseline disease burden
as a predictor of disease progression. The finding that
ubstantial progression was more common among patients
ith less disease at baseline is consistent with previous
bservations (29). The relative contribution of more pro-
Figure 1 Forest Plot of Independent Predictors of Atheroma Pr
Forest plot illustrating the independent predictors of atheroma progression in patie
variable analysis, including all univariate predictors and cardiovascular risk factors
dard deviation. The x-axis was on a logarithmic scale. APOB  apolipoprotein B; C
confidence limit; PAV  percent atheroma volume; SBP  systolic blood pressure;
easures of Atheroma Burdennd Vessel Wall DimensionsTable 3 Measures of Atheroma Burdenand Vessel Wall Dimensions
Characteristic
Progressors
(n  200)
Nonprogressors
(n  751) p Value
Baseline
Percent atheroma volume 34.5 8.4 39.3 8.8 0.001
Total atheroma volume, mm3 169.2 71.7 192.4 79.1 0.001
EEM volume, mm3 491.9 172.6 486.3 164.9 0.91
Lumen volume, mm3 322.7 124.5 293.9 107.8 0.008
Change from baseline
Percent atheroma volume 3.83 0.22 1.14 0.17 0.001
Total atheroma volume, mm3 8.36 1.86 10.38 1.56 0.001
EEM volume, mm3 21.62 3.82 13.42 3.00 0.01
Mean follow-up duration, days 654.3 105.2 674.4 107.3 0.02
easures of atheroma burden and vessel wall dimensions at baseline, and their least squares
ean  SEM change on serial evaluation.
EEM  external elastic membrane.ression in these vessels or a greater likelihood of regression
n extensively diseased arteries remains to be determined.
A number of caveats with regard to the current analysis
hould be noted. This analysis represents an observational
tudy that used pooled data from clinical trials and makes no
nferences about the use of specific treatment strategies. While
here was some heterogeneity across studies, all trials were
onducted by the same group, using identical imaging proto-
ols and with analysis by 1 core laboratory. Use of a mixed
odel statistical approach was applied to account for potential
ifferences between studies. Nevertheless, we cannot exclude
he possibility that there is residual heterogeneity in the analysis
espite adopting these measures. It should also be noted that
lthough there was no relationship with events, that these
tudies are small and not sufficient and powered to examine the
ssociation between plaque progression and outcomes. This
ssociation requires ongoing exploration in larger studies.
onclusions
espite receiving intensive medical therapy and achieving
ery low LDL-C levels, 20% of patients with coronary
rtery disease continue to demonstrate atheroma progres-
ion. While achieving a very low LDL-C level is essential
or cardiovascular prevention, the greatest impact is likely to
e derived from the use of a combination of lifestyle and
harmacological therapies that reduce global risk, by target-
ng multiple risk factors. Furthermore, differences in terms
f apoB may reflect that achieving a LDL-C level 70
sion
ith on-treatment low-density lipoprotein cholesterol (LDL-C) 70 mg/dl on multi-
ratios (ORs) of the changes data were calculated from the changes per stan-
nfidence limit; HDL-C  high-density lipoprotein cholesterol; LCL  lower
upper confidence limit.ogres
nts w
. Odds
L  co
UCL 
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hese findings further highlight the multifactorial nature of
therosclerotic cardiovascular disease and the ongoing need to
mprove current risk marker strategies.
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APPENDIX
or a description of the “poolability” of the 7 trials in this study,
progression of atherosclerosis in patients with abdominal obesity and please see the online version of this article.
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